Compare PROK & ZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROK | ZTR |
|---|---|---|
| Founded | 2015 | 1988 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.1M | 357.2M |
| IPO Year | N/A | N/A |
| Metric | PROK | ZTR |
|---|---|---|
| Price | $2.48 | $6.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.40 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 219.4K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.09% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $744,000.00 | N/A |
| Revenue This Year | $956.51 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $4.50 |
| 52 Week High | $7.13 | $6.60 |
| Indicator | PROK | ZTR |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 41.13 |
| Support Level | $2.10 | $6.25 |
| Resistance Level | $2.29 | $6.34 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 76.53 | 1.21 |
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.